| 摘要: |
| 目的：探讨孟鲁司特钠联合卡络磺钠对儿童过敏性紫癜的应用价值。方法：选取2014年1月至2017年1月我院收治并确诊的过敏性紫癜患儿128例，按照随机数表法分为研究组和对照组各64例。两组患儿基础治疗护理相同，研究组患儿给予孟鲁司特钠联合卡络磺钠治疗，对照组给予孟鲁司特钠治疗，观察两组患儿的临床症状消退时间、临床疗效、不良反应发生情况及血清IL-6、TNF-α、细胞因子信号转导抑制蛋白3（SOCS3）、低糖基化IgA1（Gd-IgA1）水平。结果：研究组患儿的皮肤紫癜、消化道病变、关节肿痛、肾脏病变消失时间均短于对照组（P均<0.01）。研究组总有效率为93.75%，高于对照组的73.44%（P<0.01）；研究组不良反应发生率为20.31%，与对照组的18.75%比较，差异无统计学意义（P>0.05）。两组患儿治疗后IL-6、TNF-α、SOCS3 mRNA、Gd-IgA1水平均下降，且研究组均低于对照组（P均<0.05）。结论：孟鲁司特钠联合卡络磺钠能够有效治疗儿童过敏性紫癜，减轻炎症反应，降低血清SOCS3、Gd-IgA1水平，改善毛细血管通透性，值得临床推广应用。 |
| 关键词: 孟鲁司特 卡络磺钠 儿童过敏性紫癜 细胞因子信号转导抑制蛋白3 低糖基化IgA1 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2020.02.005 |
|
| 基金项目: |
|
| Montelukast Sodium Combined with Carosulfone Sodium on Children with Henoch-Schöenlein Purpura and Its Effects on Serum Cytokines, Recombinant Suppressors of Cytokine Signaling 3 and Galactose-Deficient IgA1 Levels |
| Yang Jie, Wu Chunqing, Wang Xueping |
| (Maternal and Child Health Hospital of Qinhuangdao, Hebei Qinhuangdao 066000, China) |
| Abstract: |
| Objective: To explore the application value of montelukast sodium combined with carosulfone sodium on children with Henoch-Schöenlein purpura. Methods: Totally 128 children with Henoch-Schöenlein purpura admitted into our hospital from Jan. 2014 to Jan. 2017 were extracted to be divided into the control group and the study group via the random number table, with 64 cases in each group. The basic treatment and nursing of two groups were the same. The study group was treated with montelukast sodium combined with calosulfonate sodium, while the control group received montelukast sodium. The disappearance time of clinical symptoms, clinical efficacy, adverse drug reactions and levels of IL-6, TNF-α, recombinant suppressors of cytokine signaling 3 (SOCS3) and galactose-deficient IgA1 (Gd-IgA1) of two groups were observed. Results: The disappearance time of skin purpura, digestive tract disease, joint swelling and pain, kidney disease of the study group was shorter than that of the control group (P<0.01). The total effective rate of the study group was 93.75%, higher than 73.44% of the control group (P<0.01). The incidence of adverse drug reactions in the study group was 20.31%, compared with 18.75% in the control group, the difference was not statistically significant (P>0.05). After treatment, the levels of IL-6, TNF-α, SOCS3 mRNA and Gd-IgA1 in two groups decreased significantly, and the study group was lower than the control group (P<0.05). Conclusion: Montelukast sodium combined with carosulfone sodium in the treatment of children with Henoch-Schöenlein purpura is significant, which can reduce the inflammatory response and levels of serum SOCS3 and Gd-IgA1 and improve capillary permeability. It is worthy of clinical application. |
| Key words: montelustet carlosulfonate sodium children Henoch-Schoenlein purpura recombinant suppressors of cytokine signaling 3 galactose-deficient IgA1 |
